Ibrutinib (IMBRUVICA, Pharmacyclics LLC) is a first-in-class Bruton tyrosine kinase (BTK) inhibitor that is indicated in a range of hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and mantle cell lymphoma.1 Though ibrutinib is generally well tolerated, clinically significant bleeding events have been reported with the use of this medication.2 Knowledge of the potential bleeding complications is essential when treating patients who are taking ibrutinib and undergoing cutaneous surgery, especially on the face, to avoid adverse patient outcomes.
Parra CE, Newsom E, Lee EH, Allan JN, Minkis K. Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery. JAMA Dermatol. 2017;153(10):1069–1070. doi:10.1001/jamadermatol.2017.1877
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: